about
Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literatureUpdate on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 122012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides[Adult Langerhans cell histiocytosis].Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.Gender-specific differences in Adamantiades-Behçet's disease manifestations: an analysis of the German registry and meta-analysis of data from the literature.Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials.Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis.Autoimmune diseases in HIV-infected patients: 52 cases and literature review.Central nervous system involvement in Wegener granulomatosis.Urogenital manifestations in Wegener granulomatosis: a study of 11 cases and review of the literature.Population-based prevalence study of Behçet's disease: differences by ethnic origin and low variation by age at immigration.HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies.Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies.[Clinical aspects and treatment of recurrent aphthous ulcers].[Epidemiology of Behçet's disease].Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitisProgress towards a core set of outcome measures in small-vessel vasculitis. Report from OMERACT 9.IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis.Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysisMeta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritisAssessment of the item selection and weighting in the Birmingham vasculitis activity score for Wegener's granulomatosis.Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden.Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014.A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis.Epidemiology and etiology of wegener granulomatosis, microscopic polyangiitis, churg-strauss syndrome and goodpasture syndrome: vasculitides with frequent lung involvement.Effect of race/ethnicity on risk, presentation and course of connective tissue diseases and primary systemic vasculitides.Therapeutic plasma exchange in systemic vasculitis: an update on indications and results.Epidemiology of immunoglobulin A vasculitis (Henoch-Schönlein): current state of knowledge.Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management.Diagnosis and management of Neuro-Behçet's disease: international consensus recommendationsClassification and classification criteria for vasculitis: achievements, limitations and prospects.Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study.Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.Mycophenolate mofetil vs azathioprine for remission maintenance in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial.Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016.Kawasaki disease in adults: Observations in France and literature review.Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA).
P50
Q27008053-B45B64FE-9E49-4B61-A842-8E5BF3B73E33Q28081372-E7B840BC-B488-4408-ADAD-D5E625F68842Q28276589-D031F90B-1F08-439F-834B-62A47F0DEF64Q30241752-2696C809-8E58-4D1E-8E06-BFEFD75E9908Q30696868-634897EE-35AC-4AA0-88A9-44EA84EE414AQ30842385-C8E0787D-45B7-4D68-8F75-17B7B553D9DEQ30849537-8C2FFCE6-7FAF-4908-893C-9EA8F6495C76Q31120357-F85FC7EC-D9D2-4E34-B187-CA391BE35456Q33414717-506D514C-87DD-486D-AEFD-AC22FC47F837Q33993983-26091671-3859-444F-992C-08A31FEB1051Q34258754-D316557A-B37B-48D6-B243-F85ECB8A6245Q34600942-83437A06-CFAB-4859-A5D8-2A66ECE701C6Q34612338-02578C02-31E1-4982-9BD9-F69B151826AAQ34635091-C4AF62A1-F54B-401B-A477-F56C6D837C78Q34642268-B38AFC3E-7975-4D36-BC64-8D5EEDF34F08Q34658746-E74496FF-0D1A-4A5E-8899-3BFD5DBFAF8DQ35082362-0DC7570E-E5E0-4EB0-B593-C726CEDF1249Q35114049-8678ADDE-1ED7-4BD5-AE88-43581C5BDFDDQ35124613-6752B971-4A0E-4E21-B02C-6D636489E83AQ35651433-7A6CB7D6-3976-428A-A707-A2D2ABF669F3Q35754787-182F8527-4814-4FC4-A555-815A9B083AC4Q36183352-1B6EC1EE-EC87-4214-8D44-701D94F38294Q36820874-0574F93C-675F-4C96-9417-7DF8823A6E98Q36842283-3574B092-7DC0-4174-A0E2-854EBC4296E6Q37082891-30829E4E-079E-42A4-9624-F73F96349D70Q37575470-2A4ED827-3D08-46D6-8957-B69B2819D976Q37889749-31182FD9-C19D-4536-AD98-14A31BA8E144Q37976285-DC1187F0-0C4D-4EF4-9E70-5DA423EC56B8Q37997896-99E86CFE-4AD1-42C4-A300-367002672552Q38074055-BF821BF8-2623-43C8-9D93-84FF8E718364Q38164506-C73D310F-C143-4D70-9DA3-C54AB7687C92Q38173702-5823AC7D-9AC7-4732-8DF4-BD03438E3636Q38270313-EE2C96E2-93CE-4E4F-9F14-6CA02E3E2308Q38389842-1B0A2AAC-7E04-429D-8F16-B50195C649A0Q38458030-5D63C5A3-C890-4CB1-8B41-D241E9DA4F02Q38477765-5D564FB3-2C34-40F6-BEC8-894D342B40F3Q38497908-3F3DE73A-9409-4003-8AFB-1C41493F17FCQ38597229-2FBFD3C7-CCFC-4BF3-8029-41BE55386005Q38657426-7A790467-6AFB-443C-984F-10814D5A39E9Q38718798-6CA5B38E-4A28-49FB-825B-058B60100F4F
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Alfred D Mahr
@ast
Alfred D Mahr
@en
Alfred D Mahr
@es
Alfred D Mahr
@nl
Alfred D Mahr
@sl
type
label
Alfred D Mahr
@ast
Alfred D Mahr
@en
Alfred D Mahr
@es
Alfred D Mahr
@nl
Alfred D Mahr
@sl
altLabel
Alfred D Mahr
@en
prefLabel
Alfred D Mahr
@ast
Alfred D Mahr
@en
Alfred D Mahr
@es
Alfred D Mahr
@nl
Alfred D Mahr
@sl
P108
P214
P106
P1960
nXzCxPcAAAAJ
P21
P214
P31
P496
0000-0002-1564-9115
P734
P735
P7859
viaf-199888305